TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Cocaine Craving (CCQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Cocaine Craving (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Cocaine Urine Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of abdominal wall depths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: antibiotic courses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Biopsy unfinished rates
Endpoint domain: Adverse events/effects
Primary endpoint: Hospitalization rate due to biopsy
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Improvement in non-alcoholic steatosis (NAS) activity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Intra-peritoneal pressure score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Challenging behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SVI (Stroke Volume Index) Value Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Best Corrected Visual Acuity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Plasma Concentration-time at Time t (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of skin erythema index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline of skin redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline of Transepidermal water loss (TEWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline of Superficial skin hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Intraoperative analgesic consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Facial Nerve Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AUC 0-12hr of Tacrolimus Formulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Tacrolimus Formulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Western Ontario Rotator Cuff Index (WORC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients with prednisone ≤ 0.1mg/kg per day and sustained inactive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urine cotinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in serum oxidative stress marker levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in % Activated CD8+ T Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Emotional eating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in average neuroma foot pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUROC of the prediction algorithm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Open Set Monosyllabic Word Recognition Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Signal-to-Noise Ratio (SRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful uterus transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: children's behavior problems and expressions of dysregulated aggressive and violent themes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: children's compromised executive functions, language and intellectual skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Visual Analogue Scale (VAS) Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer-Motor Assessment Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative probability of testosterone at castrate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: risk of radiogenic breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Curative Resection Rate of Laparoscopic TME
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic Response of Thermo-radio-chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Event of Laparoscopic TME and Hyperthermia With CCRT
Endpoint domain: Adverse events/effects
Primary endpoint: Total isothiocyanates (ITC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kilocalories/week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subsequent drug use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CGM percent time over 140 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Fugl-Meyer Motor Impairment Score at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change from Baseline Action Research Arm Test (ARAT) score at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change from Baseline Motricity Index score at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change from Baseline ADL, Hand and Recovery Scales within Stroke Impact Scale, at 4 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline in Sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change from baseline in Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Efficacy of Oral TA and COCP in reducing menorrhagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Clinical Dementia Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in AUC0-18 of the Temozolomide Concentration (AUC-T)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Apnea-Hypopnea Index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Transcutaneous carbon dioxide tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical and radiological outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Occlutech PmVSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of Occlutech PmVSD
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline Preschool Respiratory Assessment Measure (PRAM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline O2 saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in frequency of heavy drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in endorsed negative alcohol consequences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of premature infants screened for retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Mean blood velocity of middle cerebral artery (VMCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Lyme Disease
Endpoint domain: Mortality/survival
Primary endpoint: Changes in step count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Korea-ADHD Rating scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tolerance assessed by Bristol Stool Chart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Compliance assessed by questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pharmacokinetics of total radioactivity in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of parent TZP-101 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for adaptive re-planning
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety of the neoantigen vaccine treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of failed spinal block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Specificity and sensitivity of the ARIES Bordetella Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Individual Plasma Proteins Changed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apical-cervical width of keratinized tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of progression, remaining unchanged, or regression of the distal esophageal metaplastic mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: IPI survival rate
Endpoint domain: Mortality/survival
Primary endpoint: definitive implant survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Weight bearing computed tomography parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait Analysis parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants in Each Level of Wheeze Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage change in the level of LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Target achievement rate in the level of LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Model-Based Geometric Mean Ratio (GMR) of 24-Hour Coughs Per Hour at Week 24/Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced At Least One Adverse Event (AE) During Treatment and Follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Discontinued a Study Drug Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Change in behavioral intent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: leg's length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: measure of hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: capacity to get out of bed
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rabies Virus Neutralizing Activity (RVNA) of Geometric Mean Concentration (GMC) at Study Day 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Probable or Confirmed Rabies Cases
Endpoint domain: Mortality/survival
Primary endpoint: Urinary cysteine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of parastomal hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Systemic immune activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentages of cCR and near-cCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: percentages of pCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in the Expression of FcεRI Receptors of Blood Basophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in the Expression of FcεRI Receptors of Dendritic Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-1 beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TNF alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: changes from baseline in Visual Analogue Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dose of Sedative required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Snoring Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bed Partner Sleep Quality - Actigraphy
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of successes per number of evaluable samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of time from first diagnosis of metastatic disease until death
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Solicited Local or Systemic Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change in clinical signs of caries lesion progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain activity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secondary memory score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Microvascular flow index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Cmax) of (1'-OH) Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of occurrence of Cmax (tmax) of (1'-OH) Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of (1'-OH) Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent terminal half-life (t1/2) of (1'-OH) Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve From Zero to the Last Quantifiable Concentration (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in retinal capillaries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Freedom from AF or atrial tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aqueous Humor Concentration of Study Drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to safe oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in surface electromyography (sEMG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in hand held dynamometric (HHD) measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Evaluation of the mechanical properties of the muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Evaluation of the back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Evaluation of the pressure-pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of MRSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in number of negative health events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Reaching Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality within 28 days after birth
Endpoint domain: Mortality/survival
Primary endpoint: proportion of patients free of any stroke or TIA
Endpoint domain: Mortality/survival
Primary endpoint: Mean velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and Toxicity Assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Self-Ordered Pointing Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Trail-Making
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Timed Instrumental Activities of Daily Living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Retention in and adherence to HIV care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement of edema in lower limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage IPA after 20µmol/l ADP at 2 hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration [Cmax] of PTC596
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Concentration of PTC596
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of CD4+ T cells expressing CD32 alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of CD4+ T cells expressing X alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of CD4+ T cells expressing both CD32 and X
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantification of proviral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: self reported abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Markers of Organ Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Unintended Pregnancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Symptoms measured by Convergence Insufficiency Symptom Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Subjects With Any Medically Attended Adverse Events (MAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean days to wound coverage with split skin graft (SSG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Difference in bacterial count on the wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Isokinetic force production of the knee extensor muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Vibriocidal GMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Usual Low Back Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target vessel failure (TVF) at 1-year follow up
Endpoint domain: Mortality/survival
Primary endpoint: Target lesion failure (TLF) at 2-year follow up
Endpoint domain: Mortality/survival
Primary endpoint: Mean Area Under the Curve (AUC) of Forced Expiratory Volume in One Second (FEV-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants With Complete Response (CR), Nodular Partial Response (nPR), or Partial Response (PR)
Endpoint domain: Mortality/survival
Primary endpoint: Posterior detachment of vitreous
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lesions of the retinal periphery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of eye anomaly
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Titer of Anti-HPV-16 and Anti-HPV-18 Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pharmacokinetic profile of tranexamic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rates of Adverse Events of Special Interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic parameters of midazolam AUC0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters of midazolam Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in preference for the intervention flavour
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Levels of apoptosis in the normal colonic mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Levels of cell proliferation in the normal colonic mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Readiness to Exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Presence of myocardial fibrosis and scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes